BridgeMD
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer’s Disease (TRAILBLAZER-ALZ 5)
EU CTIS ID: 2025-522340-40-00
What this study is testing
To assess the effect of donanemab versus placebo on clinical progression in participants with early symptomatic Alzheimer’s Disease
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Participants must have gradual and progressive change in memory function reported by participants or informants for ≥ 6 months
- Participants must have an MMSE score of 20 to 28 (inclusive) at screening
- Participants must meet amyloid scan (central read) criteria
- Participants must have a study partner who will provide written informed consent to participate
You likely can't join if
- Participants must not have contraindications to MRI or PET scans
The study team makes the final eligibility decision.
Where it's taking place
- Korea, Republic of
- Australia
- United Kingdom
- China
- Taiwan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Korea, Republic of; Australia; United Kingdom; China; Taiwan. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.